Clinical-stage biotherapeutics company developing immunotherapies and using its Drug Intelligence Science (DIS®) platform to improve drug discovery and clinical success
Clinical-stage biotherapeutics company developing immunotherapies and using its Drug Intelligence Science (DIS®) platform to improve drug discovery and clinical success. DIS combines proprietary single-cell technology, microfluidics, and AI/ML analysis of patient samples to discover therapeutic targets, antibody drugs, and predictive biomarkers.